+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the effectiveness of switching to the study drugs GS-3242 combined with Lenacapavir LEN compared to continuing the standard treatment Biktarvy bictegraviremtricitabinetenofovir alafenamide, BFTAF in adults with HIV-1 infection who are virologically suppressed. This Phase 2 randomized study aims to assess the safety and efficacy of an injectable regimen of GS-3242 plus LEN versus oral BFTAF in different treatment groups over distinct time points, with Part A focusing on Week 35 and Part B on Week 26. Participants are randomly assigned to receive either oral loading doses of GS-3242 and LEN tablets followed by intramuscular IM injections of these drugs for up to 52 weeks, or to continue daily oral BFTAF for the same duration. Different dosing regimens of GS-3242 and LEN are used across groups, with some groups receiving different IM doses. The study includes both randomized and non-randomized groups across the two parts. During the study, participants will be monitored for viral load, specifically HIV-1 RNA levels, using the US FDA Snapshot Algorithm at Weeks 26, 35, and 52, as well as CD4 cell counts. Safety is assessed by recording treatment-emergent adverse events throughout the study period. Drug concentrations are also measured at specific weeks to evaluate pharmacokinetics. The total participant involvement can last up to 52 weeks, with regular assessments to evaluate treatment efficacy and safety.

Age: 18Years +All GendersPhase 2
57 locations
E

Actively Recruiting

Researchers are evaluating a new long-acting injectable treatment combining lenacapavir LEN, teropavimab TAB, and zinlirvimab ZAB compared to injections of cabotegravir CAB and rilpivirine RPV given every 8 weeks in adults with HIV-1 whose virus is well controlled on daily oral treatment. The study aims to determine which regimen better maintains viral suppression after one year 52 weeks of treatment. Participants will be randomly assigned to one of two groups. One group receives oral LEN on Day 1, subcutaneous LEN and intravenous infusions of TAB and ZAB on Day 1, then oral LEN on Day 2, followed by subcutaneous LEN and IV infusions of TAB and ZAB every 26 weeks up to Week 92. The other group discontinues their current oral therapy and receives intramuscular injections of CAB and RPV on Day 1, Week 4, and then every 8 weeks up to Week 92. After Week 92, eligible participants may continue LEN TAB ZAB in an extension phase until its completion or discontinuation. During the study, participants will undergo regular monitoring of their HIV-1 RNA levels to assess viral suppression, along with measurements of CD4 T-cell counts. Safety is tracked through adverse event reports and blood tests. The primary outcome is the proportion of participants with HIV-1 RNA at or above 50 copiesmL at Week 52. Secondary outcomes include viral load at Week 92, immune cell changes, drug concentration levels, and antibody development. The total study duration extends up to approximately seven years, including follow-up and extension phases.

Age: 18Years +All GendersPhase 3
19 locations